Zenas BioPharma shared its research plans for obexelimab and updated on its drug ZB021.

Oct 31, 2026, 10:44 AM ETTrialRead the original at tradingview.com

Good for ZBIO

Zenas BioPharma has obexelimab under FDA review and filed an application in Europe, while ZB021 reduced arthritis signs in animal models. Neither treatment is approved, and ZB021 is still being tested for safety in people, but both programs have advanced.

ZBIO · Zenas BioPharma

AI read · Good for ZBIO

The AI's read

That gives Zenas progress on 2 treatments. Obexelimab has reached the application stage in the US and Europe, and ZB021 showed effects in animal tests. Neither treatment is approved, and ZB021 is still being tested for safety in people. The progress supports a positive reading, but patient benefit remains unproven.

Get alerts for ZBIO

Follow Zenas BioPharma (ZBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ZBIO

Free on the App Store and Google Play, or on the web.